logo
logo

OncoImmune, Inc. Raises $56 Million Series B Financing for Novel Cancer and COVID-19 Therapeutics

Sep 09, 2020•almost 5 years ago

Amount Raised

$56 Million

Round Type

series b

Description

OncoImmune, Inc. announced the completion of a $56 million financing in Series B equity co-led by HM Capital and a blue-chip investor. Existing investors, 3E Bioventures Capital and Kaitai Capital, as well as additional new investors, GBA Fund and GF Xinde, also joined the round. Oncoimmune will use the proceeds to support its novel therapeutic programs in late stage clinical trials and to expand its product pipeline.

Company Information

Company

About

AccelFoods is an early-stage venture fund investing in consumer products. We partner with entrepreneurs to bring innovative, high-quality food and beverage products to the forefront of the industry and create the next generation of enduring brands. With nearly $40m under management, we are hands-on partners that work tactically with our founders to scale their businesses quickly and smartly. We connect the dots within the broader food & beverage ecosystem to provide unique access, share distinct expertise, and build solid infrastructure.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Related People